Global Blood Plasma Market: Industry Analysis & Outlook (2018-2022)
Plasma forms 50% of the composition of blood in humans. Blood plasma is crucial because it is composed of different proteins. These plasma proteins or derivatives are extracted via a process known as fractionation. These proteins have high therapeutic value because they are used in several indications and its new uses are still being explored. Of these proteins, albumin accounts highest share that is 60%, and immunoglobulin with 15% share. These two are the most common proteins extracted to treat various disease.
Blood plasma is important because it fights off foreign substances that invade the body and transport nutrients and water. North America is the largest market for blood plasma as it has the most advanced infrastructure which has helped in increasing plasma collection over the time. However, emerging economies like that of China have showed huge potential with increased imports of Albumin.
Growth factors of the global blood plasma market include progress in therapeutic protein development, new advances in production of plasma, rise in collection centers, and growing Alpha-1 market’s potential. Major trends of the market include increase in fractionation capacity, growing AATD market potential, and innovation in therapeutics. The market growth is hindered by factors such as high cost of treatment, and high R&D costs.
The report offers an in-depth analysis of the global blood plasma market. It also covers global as well as regional aspect of the market. The competitive landscape of the market is of oligopoly form with domination of major players globally. The report profiles the top notch players of the market including Shire Plc., CSL Limited, Grifols, S.A., and Octapharma Inc.
- 1. Market Overview
- 1.1 Blood Plasma
- Table 1: Components of Blood Plasma
- 1.2 Blood Plasma Derivatives
- Table 2: Blood Plasma Protein Breakup
- 1.3 Functions of Blood Plasma
- Table 3: Functions of Blood Plasma
- 1.4 Plasma Collection
- Table 4: Plasma Fractioned to Protein
- 2. Global Market Analysis
- 2.1 Global Blood Plasma Market by Value
- Table 5: Global Blood Plasma Market by Value (2013-2017)
- 2.2 Global Blood Plasma Market Forecast by Value
- Table 6: Global Blood Plasma Market Forecast by Value (2018-2022)
- 2.3 Global Blood Plasma Fractionation Capacity
- Table 7: Global Blood Plasma Fractionation Capacity (2013-2017)
- 2.4 Global Blood Plasma Fractionation Capacity Forecast
- Table 8: Global Blood Plasma Fractionation Capacity Forecast (2018-2022)
- 2.5 Global Blood Plasma Market by Type
- Table 9: Global Blood Plasma Market by Type (2017)
- 2.6 Global Blood Plasma Market Forecast by Type
- Table 10: Global Blood Plasma Market Forecast by Type (2022)
- 2.7 Global Immunoglobulin Market
- 2.7.1 Global Immunoglobulin Market Forecast by Value
- Table 11: Global Immunoglobulin Market Forecast by Value (2017-2022)
- 2.7.2 Global Immunoglobulin Market Forecast by Volume
- Table 12: Global Immunoglobulin Market Forecast by Volume (2017-2022)
- 2.7.3 Global Immunoglobulin Market Volume by Region
- Table 13: Global Immunoglobulin Market Volume by Region (2017)
- 2.7.4 Global Immunoglobulin Market by Types
- Table 14: Global Immunoglobulin Market by Types (2017)
- 2.7.5 Global Immunoglobulin Population by Indication
- Table 15: Global Immunoglobulin Population by Indication (2017)
- 2.8 Global Albumin Market
- 2.8.1 Global Albumin Market Forecast by Value
- Table 16: Global Albumin Market Forecast by Value (2017-2022)
- 2.8.1 Global Albumin Market Forecast by Volume
- Table 17: Global Albumin Market Forecast by Volume (2017-2022)
- 2.8.3 Global Albumin Market Volume by Region
- Table 18: Global Albumin Market Volume by Region (2017)
- 2.9 Global Factor VIII Market
- 2.9.1 Global Factor VIII Market Forecast by Value
- Table 19: Global Factor VIII Market Forecast by Value (2017-2022)
- 2.9.2 Global Factor VIII Market Forecast by Volume
- Table 20: Global Factor VIII Market Forecast by Volume (2017-2022)
- 2.10 Global Alpha 1 Market
- 2.10.1 Global Alpha 1 Market Forecast by Value
- Table 21: Global Alpha 1 Market Forecast by Value (2017-2022)
- 2.11 Global Blood Plasma Market by Region
- Table 22: Global Blood Plasma Market by Region (2017)
- 3. Regional Analysis
- 3.1 North America
- 3.1.1 North America’s Blood Plasma Market Forecast by Value
- Table 23: North America’s Blood Plasma Market Forecast by Value (2017-2022)
- 3.1.2 North America’s Blood Plasma Market by Type
- Table 24: North America’s Blood Plasma Market by Type (2017)
- 3.1.3 The US Blood Plasma Market
- Table 25: The US Blood Plasma Market by Key Parameters (2017)
- 3.1.4 The US Immunoglobulin Market Forecast by Value & Volume
- Table 26: The US Immunoglobulin Market Forecast by Value & Volume (2017-2022)
- 3.1.5 The US Immunoglobulin Market Volume by Segment
- Table 27: The US Immunoglobulin Market Volume by Segment (2017)
- 3.1.6 The US Albumin Market Forecast by Volume
- Table 28: The US Albumin Market Forecast by Volume (2017-2022)
- 3.2 Europe
- 3.2.1 Europe Blood Plasma Market Forecast by Value
- Table 29: Europe Blood Plasma Market Forecast by Value (2017-2022)
- 3.3 APAC
- 3.3.1 Asia-Pacific Blood Plasma Market Forecast by Value
- Table 30: Asia-Pacific Blood Plasma Market Forecast by Value (2017-2022)
- 4. Market Dynamics
- 4.1 Growth Drivers
- 4.1.1 Recent Progress in Therapeutic Protein Drug Development
- Table 31: Protein Engineering Platform Technologies (2017)
- Table 32: The US Food and Drug Administration-Approved Protein Therapeutics (2016)
- 4.1.2 New Developments in the Production of Plasma Derivatives
- 4.1.3 Increasing Plasma Collection
- Table 33: Plasma Collection in the US (2013-2017)
- 4.1.4 Increased Diagnosis of Disease Treated by Immunoglobulin
- Table 34: The US CIDP Market (2017)
- 4.1.5 Increase in Per Capita use of Immunoglobulin
- Table 35: Per Capita use of Immunoglobulin by Region (2017)
- 4.1.6 Popularity of Albumin in Asian Countries
- Table 36: Albumin Consumption Per Capita by Country (2017)
- 4.1.7 Rise in GDP Per Capita
- Table 37: Global GDP Per Capita (2013-2017)
- 4.1.8 Increased Spending on Medicines
- Table 38: Global Spending on Medicines (2010-2020)
- 4.1.9 Increasing Global Healthcare Expenditure
- Table 39: Global Healthcare Expenditure (2013-3017)
- 4.1.10 Escalating Ageing Population
- Table 40: Global Ageing Population of 60 Years or Older (2000-2030)
- 4.2 Trends & Developments
- 4.2.1 Increasing Fractionation Capacity
- Table 41: Fractionation Capacity of Key Market Players (2013-2022)
- 4.2.2 Growing AATD Market Potential
- Table 42: Global Alpha1 Patient Population (2017)
- 4.2.3 Growing Blood Plasma Market in Emerging Economies
- 4.3 Challenges & Issues
- 4.3.1 High Barriers to Entry
- 4.3.2 Challenging to Open New Plasma Centers
- 4.3.3 High R&D Costs
- 5. Competitive Landscape
- 5.1 Global Market
- 5.1.1 Global Blood Plasma Market Share
- Table 43: Global Blood Plasma Market Share by Company (2017)
- 5.1.2 Global Blood Plasma Market-Comparative Analysis of Major Players
- Table 44: Global Blood Plasma Market-Comparative Analysis of Major Players (2017)
- 5.1.3 Global Immunoglobulin Market Share
- Table 45: Global Immunoglobulin Market Share by Company (2017)
- 5.1.4 Global Albumin Market Share
- Table 46: Global Albumin Market Share by Company (2017)
- 5.1.5 Global Plasma-Derived Factor VIII Market Share
- Table 47: Global Plasma-Derived Factor VIII Market Share by Company (2017)
- 5.1.6 Global Alpha1 Market Share
- Table 48: Global Alpha1 Market Share by Company (2017)
- 5.1.7 Growth in Plasma Collection by Leading Players
- Table 49: Growth in Plasma Collection by Leading Players (2017)
- 5.2 The US
- 5.2.1 The US Blood Plasma Collection Centers by Major Players
- Table 50: The US Blood Plasma Collection Centers by Major Players (2014-2017)
- 5.2.2 The US Blood Plasma Collection Volume by Major Players
- Table 51: The US Blood Plasma Collection Volume by Major Players (2014-2017)
- 6. Company Profiles
- 6.1 Shire Plc.
- 6.1.1 Business Overview
- Table 52: Shire Plc. Revenue Share by Product (2017)
- 6.1.2 Financial Overview
- Table 53: Shire PLC’s Revenue and Net Income (2013-2017)
- 6.1.3 Business Strategies
- Table 54: Shire PLC’s Major Product Pipeline (2017)
- 6.2 CSL Limited
- 6.2.1 Business Overview
- Table 55: CSL Limited’s Revenue Share by Products (2017)
- 6.2.2 Financial Overview
- Table 56: CSL Limited’s Revenue and Net Profit (2013-2017)
- 6.2.3 Business Strategies
- Table 57: Research & Development Investments of CSL Limited (2013-2017)
- 6.3 Grifols, S.A.
- 6.3.1 Business Overview
- Table 58: Grifols, S.A. Revenue Share by Business Segments (2017)
- 6.3.2 Financial Overview
- Table 59: Grifols, S.A. Revenue and Gross Profit (2013-2017)
- 6.3.3 Business Strategies
- 6.4 Octapharma, Inc.
- 6.4.1 Business Overview
- 6.4.2 Financial Overview
- Table 60: Octapharma, Inc. Revenue (2013-2017)
- 6.4.3 Business Strategies